Combination Therapy Proposed for Multiple Myeloma and Mantle Cell LymphomaDecember 12th 2017
A proof-of-concept study has demonstrated that resistance to treatment in multiple myeloma and mantle cell lymphoma could be linked to a protein called Nrf1, which appears to respond to proteasome insufficiency or pharmacological inhibition.
Six-Month Analysis of CTL019 Demonstrates Sustained Responses in Refractory DLBCL PatientsDecember 11th 2017
A potentially practice-changing study presented at 2017 ASH shows high rates of sustained complete response in patients with relapsed/refractory diffuse large B-cell lymphoma who were treated with CTL019 CAR T-cell therapy.
Nivolumab Approved for Squamous Cell Carcinoma of the Head and NeckNovember 14th 2016
The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.
LUX-Lung 7 Trial Demonstrates Efficacy of Afatinib Over GefitinibJanuary 29th 2016
Second-generation, EGFR-directed therapy afatinib (Gilotrif) may be superior to first-generation gefitinib (Iressa) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive, advanced non-small cell lung cancer.